● Recruiting

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

Condition: Chronic Myelogenous Leukemia - Chronic Phase · Sponsor: Novartis Pharmaceuticals

PhaseN/A

Planned participants1000

Who can joinAll sexes, 18 Years to 100 Years

Healthy volunteersNo

About this study

This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (17)

University of Alabama at Birmingham	Birmingham, Alabama, United States	Recruiting
Stockton Hematology Oncology Medical Group Inc	Stockton, California, United States	Recruiting
Lundquist Inst BioMed at Harbor	Torrance, California, United States	Recruiting
Stamford Hospital	Stamford, Connecticut, United States	Recruiting
Sacred Heart Medical Oncology	Pensacola, Florida, United States	Recruiting
Cancer Care Specialists of Central Illinois	Decatur, Illinois, United States	Recruiting
St Agnes Hospital	Baltimore, Maryland, United States	Recruiting
Truman Medical Center	Kansas City, Missouri, United States	Recruiting
NY Cancer and Blood Specialists	East Setauket, New York, United States	Recruiting
SUNY Upstate Medical University	Syracuse, New York, United States	Recruiting
Tri-County Hematology and Oncology Associates	Canton, Ohio, United States	Recruiting
Oregon Oncology Specialists Salem	Salem, Oregon, United States	Recruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07091019